Catherine Alix-Panabières: The clinical potential of ctDNA and CTCs in bladder cancer
Catherine Alix-Panabières, Professor of Oncology at the Faculty of Medicine of the University of Montpellier, shared an article by Sia V Lindskrog, et al. on LinkedIn:
“Hot off the press!
Super excited to share our latest review just published in Nature Portfolio.
Liquid biopsies, indicating the sampling of body fluids rather than solid-tissue biopsies, have the potential to revolutionize cancer care through personalized, non-invasive disease detection and monitoring.
Circulating tumour DNA (ctDNA) and circulating tumour cells (CTCs) are promising blood-based biomarkers in bladder cancer. Results from several studies have shown the clinical potential of ctDNA and CTCs in bladder cancer for prognostication, treatment-response monitoring, and early detection of minimal residual disease (MRD) and disease recurrence.
Following successful clinical trial evaluation, assessment of ctDNA and CTCs holds the potential to transform the therapeutic pathway for patients with bladder cancer — potentially in combination with the analysis of urinary tumour DNA — through tailored treatment guidance and optimized disease surveillance.
Good reading!”
Circulating tumour DNA and circulating tumour cells in bladder cancer – from discovery to clinical implementation.
Authors: Sia V Lindskrog, et al.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023